Blue Trust Inc. Has $540,000 Stake in Haleon PLC Sponsored ADR $HLN

Blue Trust Inc. trimmed its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 5.3% in the second quarter, HoldingsChannel.com reports. The firm owned 52,096 shares of the company’s stock after selling 2,907 shares during the period. Blue Trust Inc.’s holdings in Haleon were worth $540,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of HLN. Nuveen LLC acquired a new stake in Haleon in the first quarter valued at $58,870,000. Millennium Management LLC increased its holdings in Haleon by 697.2% in the first quarter. Millennium Management LLC now owns 4,216,504 shares of the company’s stock valued at $43,388,000 after purchasing an additional 3,687,613 shares during the period. Wellington Management Group LLP increased its holdings in Haleon by 22.0% in the first quarter. Wellington Management Group LLP now owns 18,700,480 shares of the company’s stock valued at $192,428,000 after purchasing an additional 3,372,155 shares during the period. Sculptor Capital LP increased its holdings in Haleon by 22.1% in the first quarter. Sculptor Capital LP now owns 10,849,868 shares of the company’s stock valued at $111,645,000 after purchasing an additional 1,962,770 shares during the period. Finally, Jane Street Group LLC increased its holdings in Haleon by 933.1% in the first quarter. Jane Street Group LLC now owns 2,155,716 shares of the company’s stock valued at $22,182,000 after purchasing an additional 1,947,050 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HLN. Wall Street Zen cut shares of Haleon from a “buy” rating to a “hold” rating in a research report on Saturday, July 12th. Barclays cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, September 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Price Performance

HLN stock opened at $8.99 on Monday. The stock has a market capitalization of $40.01 billion, a PE ratio of 23.04, a price-to-earnings-growth ratio of 2.64 and a beta of 0.20. The company’s 50-day moving average is $9.42 and its 200-day moving average is $10.02. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42.

Haleon Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Stockholders of record on Friday, August 15th were given a dividend of $0.0555 per share. This is a boost from Haleon’s previous semi-annual dividend of $0.05. The ex-dividend date of this dividend was Friday, August 15th. This represents a dividend yield of 190.0%. Haleon’s payout ratio is currently 28.21%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.